Key result
Fasudil significantly improved monocrotaline-induced pulmonary arterial hypertension to a greater degree than bosentan and sildenafil by reducing pulmonary arterial remodelling and RV hypertrophy.
Population
Male Wistar rats with monocrotaline (MCT)-induced pulmonary arterial hypertension (40 mg/kg body weight)
Comparison
Fasudil oral treatment for 14 days, alone or in… vs Bosentan oral treatment for 14 days, sildenafil…
Design
Preclinical
Follow-up
14 days of treatment
Authors
Loading...
Does not support clinical use in pulmonary arterial hypertension; hypothesis-generating for fasudil and requires human translation studies.
In a rat model of pulmonary arterial hypertension, fasudil demonstrated superior efficacy compared to bosentan and sildenafil in improving hemodynamics and right ventricular remodeling.
Mouchaers et al. (2010) studied Pulmonary arterial hypertension (n=63). Fasudil vs. Bosentan, sildenafil, or combinations was evaluated on Right ventricular function, pulmonary arterial pressure, and pulmonary vascular resistance. Fasudil significantly improved monocrotaline-induced pulmonary arterial hypertension to a greater degree than bosentan and sildenafil by reducing pulmonary arterial remodelling and RV hypertrophy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: